Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 10/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604584 | 0.85 | HRH4 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL605328 | 0.82 | HRH4 (0.60) | HRH4POLBRAB9A | |
| SCHEMBL3422106 | 0.79 | HDAC6 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23191108 | 0.75 | ALDH1A1 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18883256 | 0.75 | ALDH1A1 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23191099 | 0.75 | ALDH1A1 (0.63) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17933710 | 0.75 | ALDH1A1 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16552182 | 0.75 | ALDH1A1 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23191043 | 0.74 | ALDH1A1 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17933708 | 0.74 | HDAC3 (0.60) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | PDE3B 4645/4885PDE3A 4777/4885HDAC3 19/4885 |
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | PDE3B 2246/4885PDE3A 2402/4885HDAC3 378/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | PDE3B 4322/4885PDE3A 4092/4885HDAC3 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.